VRAC活化NLRP3/Caspase-1/GSDMD焦亡信号通路在肠缺血再灌注后肠损伤中的作用及机制
批准号:
82072224
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
李偲
依托单位:
学科分类:
器官功能衰竭与支持
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
李偲
中文摘要
肠缺血再灌注(I/R)是导致患者死亡的重要原因之一,其机制尚未明了。已证实细胞焦亡作为一种促炎性死亡方式在组织器官I/R损伤中起重要作用,而经典焦亡信号通路NLRP3/Caspase-1/GSDMD的激活依赖细胞内K+、Cl-外流。容积调控阴离子通道(VRAC)能在低渗细胞水肿时活化,导致细胞内K+、Cl-外流。申请者前期研究发现VRAC抑制剂可减轻肠I/R后肠损伤,伴随着焦亡相关蛋白表达下调,提示VRAC通过调控焦亡参与肠损伤过程。据此,申请者推测:肠I/R导致肠上皮细胞水肿,激活VARC导致细胞内K+、Cl-外流,进而活化NLRP3/Caspase-1/GSDMD信号通路,最终引起失控的炎症反应及肠粘膜上皮细胞焦亡导致肠损伤。本项目将通过一系列体内外实验来验证该假说,为寻找防治肠I/R损伤可供干预的靶点提供理论依据。
英文摘要
Intestinal ischemia-reperfusion (I/R) is one of the most important causes of death, but its pathogenesis remains unclear. In recent years, researches have confirmed that pyroptosis is playing an important role in I/R injury, and NLRP3/Caspase-1/GSDMD is the canonical signaling pathway of pyroptosis. Potassium and chloride efflux has been proposed to have an essential function in NLRP3 inflammasome activation. Volume regulated anion channels (VRAC) can be activated in extracellular osmolarity during cell swelling, resulting in potassium and chloride efflux. We recently found that VRAC inhibitor can reduce intestinal injury after intestinal I/R, with the down-regulation of pyroptosis related protein expression. Our data identified that VRAC as a basic conserved homeostatic mechanism is associated with pyroptosis and intestinal I/R. Based on the above findings, we hypothesize that intestinal epithelial cells swelling after intestinal I/R could active of VRAC, which lead to NLRP3/Caspase-1/GSDMD signaling pathway activation. Therefore, the present study aims to verify this hypothesis via a series of in vivo and in vitro experiments. This study will provide scientific basis for seeking for therapeutic targets which can be intervened in prevention of intestinal I/R injury.
肠缺血再灌注是围手术期患者死亡的主要原因,肠缺血再灌注后会导致肠粘膜损伤,肠屏障破坏,场内菌群移位至远隔器官,可能导致局部或全身感染,继而引发脓毒症多器官衰竭。,因此,肠被认为是 MODS 的“枢纽”和“始动”器官,是导致危重症患者死亡的重要原因之一。虽然目前肠 I/R 致肠损伤的机制有很多假说,包括申请人及所在团队提出氧化应激反应、细胞坏死/凋亡/程序性坏死等。但防治肠屏障损伤,预防多器官功能障碍的具体机制上不清楚,申请人主要包括以下内容:1发现术前禁食24h处理通过重塑肠道菌群及其代谢产物从而减轻小鼠肠I/R损伤;2、聚合水凝胶纳米胶囊负载布比卡因药物递送系统用于局部麻醉药和疼痛管理;3、miRNA-124-3p通过调节SP1/HDAC4/HIF-1α通路减轻脓毒症所致心肌损伤
VDAC2乳酸化修饰调节线粒体自噬-NLRP3炎症小体轴在脓毒症心肌损伤中的作用及机制
-
批准号:82372157
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:李偲
-
依托单位:
miRNA-151调节TLR9/TRAF6信号通路在肠I/R损伤后细菌移位的作用及机制
-
批准号:81871609
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:李偲
-
依托单位:
国内基金
海外基金